Samuele Marro, PhD
Samuele Marro (Preferred Name)
- ASSISTANT PROFESSOR | Neuroscience
Research Topics:
Autism, Induced pluripotent stem cells, Neuroscience, Synaptic PlasticityI received my PhD in Human Biology from the Molecular Biotechnology Center at the University of Torino in Italy. I was trained as a postdoctoral fellow in pluripotent stem cell biology in the laboratory of Marius Wernig, MD PhD, at the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University.
I am currently an Assistant Professor in the Nash Family Department of Neuroscience and the Black Family Stem Cell Institute at the Icahn School of Medicine at Mount Sinai.
My team focuses on synaptic plasticity and its dysfunction in Fragile X syndrome, the number one genetic cause of autism. As a tool, the group uses human neurons directly differentiated from pluripotent stem cells and genetically modified using CRISPR/Cas9 tools.
I also serve as co-Director of the Stem Cell Engineering Core. This institutional Core provides services at a reduced cost to the Icahn School of Medicine community. Services include the derivation of iPS from patient blood samples, iPS differentiation into specific cell types, and gene-editing in iPS to create or repair putative disease mutations.
Multi-Disciplinary Training Areas
Development Regeneration and Stem Cells [DRS], Neuroscience [NEU]Marro S, Pang ZP, Yang N, Tsai MC, Qu K, Chang HY, Südhof TC, Wernig M. Direct lineage conversion of terminally differentiated hepatocytes to functional neurons. Cell stem cell 2011 Oct; 9(4).
Marro SG, Chanda S, Yang N, Janas JA, Valperga G, Trotter J, Zhou B, Merrill S, Yousif I, Shelby H, Vogel H, Kalani MY, Südhof TC, Wernig M. Neuroligin-4 Regulates Excitatory Synaptic Transmission in Human Neurons. Neuron 2019 08; 103(4).
Zhang Z, Marro SG, Zhang Y, Arendt KL, Patzke C, Zhou B, Fair T, Yang N, Südhof TC, Wernig M, Chen L. The fragile X mutation impairs homeostatic plasticity in human neurons by blocking synaptic retinoic acid signaling. Science translational medicine 2018 08; 10(452).
Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S, Marro S, Patzke C, Acuna C, Covy J, Xu W, Yang N, Danko T, Chen L, Wernig M, Südhof TC. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 2013 Jun; 78(5).
Marro S, Barisani D, Chiabrando D, Fagoonee S, Muckenthaler MU, Stolte J, Meneveri R, Haile D, Silengo L, Altruda F, Tolosano E. Lack of haptoglobin affects iron transport across duodenum by modulating ferroportin expression. Gastroenterology 2007 Oct; 133(4).
Marro S, Chiabrando D, Messana E, Stolte J, Turco E, Tolosano E, Muckenthaler MU. Heme controls ferroportin1 (FPN1) transcription involving Bach1, Nrf2 and a MARE/ARE sequence motif at position -7007 of the FPN1 promoter. Haematologica 2010 Aug; 95(8).
Nobuta H, Yang N, Ng YH, Marro SG, Sabeur K, Chavali M, Stockley JH, Killilea DW, Walter PB, Zhao C, Huie P, Goldman SA, Kriegstein AR, Franklin RJ, Rowitch DH, Wernig M. Oligodendrocyte Death in Pelizaeus-Merzbacher Disease Is Rescued by Iron Chelation. Cell stem cell 2019 Oct; 25(4).
Yang N, Chanda S, Marro S, Ng YH, Janas JA, Haag D, Ang CE, Tang Y, Flores Q, Mall M, Wapinski O, Li M, Ahlenius H, Rubenstein JL, Chang HY, Buylla AA, Südhof TC, Wernig M. Generation of pure GABAergic neurons by transcription factor programming. Nature methods 2017 Jun; 14(6).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Marro during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- DORIAN THERAPEUTICS, INC.; TURN BIOTECHNOLOGIES, INC
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.